The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.75
Bid: 32.50
Ask: 33.00
Change: 0.25 (0.76%)
Spread: 0.50 (1.538%)
Open: 32.75
High: 33.50
Low: 33.00
Prev. Close: 32.75
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sch 1 Update - Duke Royalty Limited

22 Mar 2017 15:45

RNS Number : 2396A
AIM
22 March 2017
 

 

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

COMPANY NAME:

 

Duke Royalty Limited (the "Company" or "Duke")

 

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :

 

4th Floor, West Wing

St Peter Port

Guernsey

GY1 2JA

 

COUNTRY OF INCORPORATION:

 

Guernsey

 

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

 

www.dukeroyalty.com/

 

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

 

Duke was incorporated as Praetorian Resources Limited in 2012 and established as a natural resource investment vehicle. On 16 June 2015, Shareholders resolved to amend the Company's investing policy to invest in a diversified portfolio of royalty finance and related opportunities and to change its name to Duke Royalty Limited. On 29 March 2016, the Company announced the sale of the last of its natural resource investments and is now seeking re-admission to AIM as a Rule 8 investing company to enable it to implement its investing policy, which is detailed below:

 

To build a stable and reliable income for Shareholders by seeking to invest in, without limitation and restrictions (including geographic restrictions):

 

(i) long-term, revenue-based royalties in private and/or public companies; and/or

(ii) other alternative asset classes and/or financing instruments from time to time that bear similar risk and return characteristics to the investments in paragraph (i).

 

 

The Company has built a near-term pipeline of potential Royalty Financing transactions

amounting to approximately £75 million. Duke will provide financing to Royalty Partners in one or more instalments in return for monthly royalty payments.

 

 

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

 

Number of Ordinary Shares of no par value to be admitted: 45,377,459

 

The shares are freely transferable and have no restrictions placed on them.

 

CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

 

Capital raised on admission: £15.0 million

 

Market capitalisation on admission: £18.2 million

 

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

 

Percentage of AIM securities not in public hands at admission: 29%

 

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM COMPANY HAS APPLIED OR AGREED TO HAVE ANY OF ITS SECURITIES (INCLUDING ITS AIM SECURITIES) ADMITTED OR TRADED:

 

The Company is not listed on any other exchange.

 

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

 

Nigel Norman Birrell (Non-Executive Chairman)

Neil Allan Johnson (Chief Executive Officer)

Charles (Charlie) Cannon-Brookes (Executive Director)

James (Jim) Alan Ryan (Non-Executive Director)

Mark Wilson Le Tissier (Non-Executive Director)

 

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

 

Shareholder Name

Percentage Holding before Admission

Percentage Holding after Admission

Neil Johnson (1)

11.55%

3.66%

Artemis Investment Management plc

5.78%

3.76%

Charlie Cannon-Brookes (2)

5.76%

6.10%

Jim Ryan

5.08%

1.43%

Nigel Birrell

5.08%

1.16%

Richard Lockwood (3)

4.87%

2.72%

Justin Cochrane

4.00%

1.52%

APAC Resources Limited

3.31%

0.57%

Malcolm Burne

3.30%

0.85%

Ravenscroft Ltd

3.17%

2.58%

Hargreave Hale Limited

0%

16.53%

Partner Value Investments Inc

0%

9.64%

AXA Investment Managers

0%

8.26%

Walker Crips Group plc

0%

4.41%

Henderson Global Investors Limited

0%

3.31%

 

(1) Of this percentage holding, 6.35 per cent. before Admission and 1.10 per cent. after Admission is legally owned by Abingdon Capital Corporation. Neil Johnson is Abingdon's sole voting shareholder.

(2) Of this percentage holding, 3.74 per cent. before Admission and 2.99 per cent. after Admission is legally owned by Arlington Group Asset Management Limited ("Arlington"). Charlie Cannon-Brookes is the investment director of Arlington and holds 40 per cent. of the voting shares of Arlington.

(3) Richard Lockwood is a director of Arlington and holds 20 per cent. of the voting shares of Arlington.

 

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

 

WH Ireland Group plc

Ravenscroft Limited

CED Capital Limited

2428555 Ontario Inc

 

(i) ANTICIPATED ACCOUNTING REFERENCE DATE

(ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

(iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

 

(i) 31 March

(ii) No historical financial information is being included in the AIM admission document. The date of the last notified accounts of the Company was 30 September 2016

(iii) audited results for the year to 31 March 2017 by 30 September 2017;

unaudited interim results for the six months to 30 September 2017 by 31 December 2017;

audited results for the year to 31 March 2018 by 30 September 2018

 

EXPECTED ADMISSION DATE:

 

23 March 2017

 

NAME AND ADDRESS OF NOMINATED ADVISER:

 

Grant Thornton UK LLP

30 Finsbury Square

London

EC2P 2YU

 

NAME AND ADDRESS OF BROKER:

 

Cantor Fitzgerald Europe

One Churchill Place

London

E14 5RB

 

Mirabaud Securities LLP

33 Grosvenor Place

London

SW1X 7HY

 

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

 

The Admission Document, containing full details about Duke Royalty Limited and the admission of its issued share capital to trading on AIM, will be available during normal business hours on any weekday (excluding Saturdays, Sundays and public holidays) at the registered office of McCarthy Tétrault, 26th Floor, 125 Old Broad Street, London, EC2N 1AR and the registered office of the Company until at least one month after Admission.

 

Copies of the Admission Document will also be available on the Company's website at www.dukeroyalty.com following Admission.

 

DATE OF NOTIFICATION:

22 March 2017

 

NEW/ UPDATE:

 

UPDATE

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AIMPGUUCWUPMGAP
Date   Source Headline
30th Aug 20223:07 pmRNSHolding(s) in Company
5th Aug 20227:00 amRNSNotice of Results and Presentations
4th Aug 20227:00 amRNSTrading Update
21st Jun 20227:00 amRNSInterim Dividend and Dividend Declaration
1st Jun 20224:25 pmRNSHolding(s) in Company
27th May 20229:08 amRNSDirector / PCA Dealings
26th May 20223:23 pmRNSResult of General Meeting and Issue of Equity
11th May 20227:05 amRNSRaises £20m through Placing and PrimaryBid Offer
10th May 20225:08 pmRNSPrimaryBid Offer
10th May 20224:44 pmRNSPlacing to raise a minimum of £15 million
28th Apr 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
20th Apr 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
11th Apr 20227:00 amRNSTrading Update
18th Mar 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
17th Mar 20227:00 amRNSIncreased Interim Dividend & Dividend Declaration
2nd Mar 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
25th Feb 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
17th Feb 20227:00 amRNSFurther re: Directorate Change
14th Feb 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
2nd Feb 20227:00 amRNSDirectorate Changes
1st Feb 202210:02 amRNSReplacement - Trading Update
1st Feb 20227:00 amRNSTrading Update
20th Jan 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
23rd Dec 20212:30 pmRNSHolding(s) in Company
23rd Dec 20217:01 amRNSTrading Update
23rd Dec 20217:00 amRNSFollow-on investment into existing Royalty Partner
22nd Dec 20213:52 pmRNSFollow-on investment into existing Royalty Partner
16th Dec 20217:00 amRNSNew Royalty Agreement
14th Dec 20217:00 amRNSIncreased Interim Dividend & Dividend Declaration
7th Dec 20217:00 amRNSEnters into Largest Royalty Agreement To Date
3rd Dec 20217:00 amRNSInterim Results
2nd Dec 20217:00 amRNSCompletion of £4.2 million Follow-On Investment
25th Nov 20217:00 amRNSNotice of Interim Results
29th Oct 20214:03 pmRNSLong Term Incentive Plan Awards
27th Oct 20217:01 amRNSFollow-On Investment into Existing Royalty Partner
27th Oct 20217:00 amRNSHolding(s) in Company
22nd Oct 20214:36 pmRNSResult of Annual General Meeting
16th Sep 20217:01 amRNSInterim Dividend and Dividend Declaration
16th Sep 20217:00 amRNSFinal Results
7th Sep 20217:00 amRNS£2.2m Follow-On Investment into Royalty Partner
2nd Sep 20217:00 amRNSHolding(s) in Company
17th Aug 20217:00 amRNSInvestor Presentation
11th Aug 20217:00 amRNSSuccessful Exit of Investment in Royalty Partner
10th Aug 20217:00 amRNSNotice of Results and Analyst Presentation
2nd Aug 20217:00 amRNSNew Royalty Agreement
26th Jul 20217:00 amRNSTrading Update
22nd Jul 20217:00 amRNSNew Royalty Agreement
1st Jul 20217:00 amRNSNew Royalty Agreement with Fairmed Healthcare AG
17th Jun 20217:00 amRNSInterim Dividend and Dividend Declaration
10th May 20217:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.